Veronica Hulstrøm

1.2k total citations · 1 hit paper
17 papers, 498 citations indexed

About

Veronica Hulstrøm is a scholar working on Epidemiology, Pulmonary and Respiratory Medicine and Immunology and Allergy. According to data from OpenAlex, Veronica Hulstrøm has authored 17 papers receiving a total of 498 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 9 papers in Pulmonary and Respiratory Medicine and 3 papers in Immunology and Allergy. Recurrent topics in Veronica Hulstrøm's work include Respiratory viral infections research (14 papers), Pneumonia and Respiratory Infections (8 papers) and Tracheal and airway disorders (6 papers). Veronica Hulstrøm is often cited by papers focused on Respiratory viral infections research (14 papers), Pneumonia and Respiratory Infections (8 papers) and Tracheal and airway disorders (6 papers). Veronica Hulstrøm collaborates with scholars based in Belgium, United States and Germany. Veronica Hulstrøm's co-authors include Nathalie De Schrevel, Tino F. Schwarz, Marie‐Pierre David, Laurence Fissette, Lusiné Kostanyan, Isabel Leroux‐Roels, Nancy Dezutter, Richard N. van Zyl-Smit, Joanne M. Langley and Alberto Papi and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Journal of Allergy and Clinical Immunology.

In The Last Decade

Veronica Hulstrøm

13 papers receiving 477 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults

2023 405 citations Alberto Papi, Michael G. Ison et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Veronica Hulstrøm Belgium	7	422	196	128	41	34	17	498
Lusiné Kostanyan United States	6	392 0.9×	184 0.9×	112 0.9×	42 1.0×	34 1.0×	9	456
Nathalie De Schrevel Belgium	7	432 1.0×	200 1.0×	122 1.0×	45 1.1×	32 0.9×	16	497
Nancy Dezutter Belgium	6	396 0.9×	189 1.0×	125 1.0×	49 1.2×	34 1.0×	11	485
Nawarat Posuwan Thailand	15	551 1.3×	155 0.8×	34 0.3×	30 0.7×	25 0.7×	36	699
Athanasios Kossyvakis Greece	12	198 0.5×	186 0.9×	34 0.3×	26 0.6×	18 0.5×	26	404
Lars Høsøien Skanke Norway	8	221 0.5×	201 1.0×	67 0.5×	22 0.5×	5 0.1×	9	337
Andreu Comas‐García Mexico	13	265 0.6×	181 0.9×	74 0.6×	54 1.3×	11 0.3×	32	431
Megan E. Schmidt United States	7	241 0.6×	233 1.2×	77 0.6×	196 4.8×	7 0.2×	12	496
Ko‐Yung Sit Hong Kong	6	145 0.3×	492 2.5×	65 0.5×	34 0.8×	19 0.6×	12	671

Countries citing papers authored by Veronica Hulstrøm

Since Specialization

Citations

This map shows the geographic impact of Veronica Hulstrøm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Veronica Hulstrøm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Veronica Hulstrøm more than expected).

Fields of papers citing papers by Veronica Hulstrøm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Veronica Hulstrøm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Veronica Hulstrøm. The network helps show where Veronica Hulstrøm may publish in the future.

Co-authorship network of co-authors of Veronica Hulstrøm

This figure shows the co-authorship network connecting the top 25 collaborators of Veronica Hulstrøm. A scholar is included among the top collaborators of Veronica Hulstrøm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Veronica Hulstrøm. Veronica Hulstrøm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Prato, Rosa, et al.. (2025). P-719. Respiratory syncytial virus (RSV) disease burden in older adults with acute respiratory infection (ARI) in Europe during the 2022/2023 RSV season. Open Forum Infectious Diseases. 12(Supplement_1).

Stranzl, Thomas, David I. Bernstein, Tomokazu Matsuoka, et al.. (2024). Consistent efficacy and safety of sublingual immunotherapy tablets across allergens and geographic regions. Allergy and Asthma Proceedings. 45(4). 232–239. 2 indexed citations

Curran, Desmond, Sean Matthews, Silvia Narejos Pérez, et al.. (2024). The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus‐associated disease in breakthrough infections in adults ≥60 years of age. Influenza and Other Respiratory Viruses. 18(2). e13236–e13236. 12 indexed citations

Germain, Sophie, et al.. (2024). Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial. Clinical Infectious Diseases. 19 indexed citations

Ferguson, Murdo, Alexander G. Murray, Lars Rombo, et al.. (2024). Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults. Vaccine X. 18. 100494–100494. 1 indexed citations

Schwarz, Tino F., Chiu-Shong Liu, Kenji Takazawa, et al.. (2023). Immunogenicity and Safety Following 1 Dose of AS01E-Adjuvanted Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults: A Phase 3 Trial. The Journal of Infectious Diseases. 230(1). e102–e110. 16 indexed citations

Nolte, Hendrik, et al.. (2023). Anaphylaxis in Clinical Trials of Sublingual Immunotherapy Tablets. The Journal of Allergy and Clinical Immunology In Practice. 12(1). 85–95.e4. 10 indexed citations

Kotb, Shady, Miwa Haranaka, Nicolas Folschweiller, et al.. (2023). Safety and immunogenicity of a respiratory syncytial virus prefusion F protein (RSVPreF3) candidate vaccine in older Japanese adults: A phase I, randomized, observer-blind clinical trial. Respiratory Investigation. 61(2). 261–269. 11 indexed citations

Ison, Michael G., Alberto Papi, Joanne M. Langley, et al.. (2023). A Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3-OA) is Efficacious in Adults ≥ 60 Years of Age (YOA). Diabetologie und Stoffwechsel. 18(S 01). S54–S54. 2 indexed citations

10.

Leroux‐Roels, Isabel, Marc Van Ranst, Corinne Vandermeulen, et al.. (2023). Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study. The Journal of Infectious Diseases. 229(2). 355–366. 7 indexed citations

11.

Nolte, Hendrik, et al.. (2023). Anaphylaxis is Uncommon in Clinical Trials of Sublingual Immunotherapy Tablets as Identified by a Standardized Algorithm. Journal of Allergy and Clinical Immunology. 151(2). AB46–AB46. 2 indexed citations

12.

Papi, Alberto, Michael G. Ison, Joanne M. Langley, et al.. (2023). Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. New England Journal of Medicine. 388(7). 595–608. 405 indexed citations breakdown →

13.

Papi, Alberto, Robert G. Feldman, Raffaele Antonelli Incalzi, et al.. (2023). Late Breaking Abstract - Efficacy of a respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults with co-existing cardiorespiratory conditions. OA4859–OA4859.

14.

Quinn, Dean, Mohammed Bensellam, Nathalie De Schrevel, et al.. (2022). 2139. Immunogenicity, reactogenicity and safety of a Respiratory Syncytial Virus prefusion F (RSVPreF3) candidate vaccine co-administered with the seasonal quadrivalent influenza vaccine in older adults. Open Forum Infectious Diseases. 9(Supplement_2).

15.

Schwarz, Tino F., Chiu-Shong Liu, Kenji Takazawa, et al.. (2022). 96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination. Open Forum Infectious Diseases. 9(Supplement_2). 4 indexed citations

16.

Ison, Michael G., Alberto Papi, Joanne M. Langley, et al.. (2022). LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA). Open Forum Infectious Diseases. 9(Supplement_2). 5 indexed citations

17.

Schwarz, Tino F., Chiu-Shong Liu, Kenji Takazawa, et al.. (2022). 119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination. Open Forum Infectious Diseases. 9(Supplement_2). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact